Clovertex’s October Target of the Month is human serum albumin, the body’s most abundant circulating...
Clovertex’s September 2025 Target of the Month is LGR5, in light of Genmab’s announcement that it wi...
After a bit of a break, we're back with our Hottest Social roundup. On the technical front, cryo-EM ...
Clovertex’s August 2025 Target of the Month is MC4R (melanocortin‑4 receptor). MC4R is a GPCR that p...
Clovertex’s June Target of the Month is KIT, highlighted by Sanofi’s acquisition of Blueprint Medici...
Clovertex’s May Target of the Month is B-Raf, a serine/threonine kinase that plays a central role in...
Bitter days for the industry, sweet days for cryo-EM. This month’s SBDD social pulse captures a stri...
Clovertex’s April 2025 Target of the Month is the neonatal Fc receptor (FcRn), following the U.S. FD...
April delivered no shortage of turbulence — but also a few genuine bright spots. Amid ongoing instab...
Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...